PainReform Ltd. (PRFX)
NASDAQ: PRFX · IEX Real-Time Price · USD
0.505
-0.034 (-6.31%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Company Description
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel.
It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.
The company was incorporated in 2007 and is based in Tel Aviv, Israel.
PainReform Ltd.
Country | Israel |
Founded | 2007 |
IPO Date | Sep 1, 2020 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 7 |
CEO | Ilan Hadar M.B.A. |
Contact Details
Address: 65 Yigal Alon St. Tel Aviv, L3 6744316 Israel | |
Phone | 972-3-7177051 |
Website | painreform.com |
Stock Details
Ticker Symbol | PRFX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $8.00 |
CIK Code | 0001801834 |
CUSIP Number | M77798102 |
ISIN Number | IL0011651580 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Ilan Hadar M.B.A. | Chief Executive Officer and Chief Financial Officer |
Dr. Ehud Geller Ph.D. | Executive Chairman |
Dr. Sigal Aviel | Chief Operating Officer |
Prof. Eli Hazum Ph.D. | Chief Technology Officer and Director |
Rita Keynan | Vice President of Pharmaceutical Operations |
Dr. Stephen A. Cooper D.M.D Ph.D. | Executive Vice President of Development |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jul 9, 2024 | 6-K | Report of foreign issuer |
Jun 26, 2024 | 6-K | Report of foreign issuer |
May 31, 2024 | 6-K | Report of foreign issuer |
May 15, 2024 | 6-K | Report of foreign issuer |
Apr 24, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Apr 17, 2024 | 6-K | Report of foreign issuer |
Apr 17, 2024 | 424B3 | Prospectus |
Apr 17, 2024 | 424B4 | Prospectus |
Apr 16, 2024 | 6-K | Report of foreign issuer |
Apr 15, 2024 | EFFECT | Notice of Effectiveness |